Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 29Gastrointestinal 5Genitourinary 4CNS 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 14Neoplasms 5Adenocarcinoma of Lung 4Carcinoma, Renal Cell 3Small Cell Lung Carcinoma 2Sarcoma 2Mesothelioma 2Colorectal Neoplasms 2Breast Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Solitary Fibrous Tumor, Pleural 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 38Docetaxel 23Paclitaxel 20Trastuzumab 19Cyclophosphamide 18Gemcitabine 17Carboplatin 17Magnetic Resonance Spectroscopy 16Radiotherapy 14Nivolumab 13Radiosurgery 12Surveys and Questionnaires 11Specimen Handling 10Fulvestrant 10fludarabine 9aldesleukin 9Vinorelbine 9Blood Specimen Collection 9Taxes 8Injections 8Drug Therapy 8Cisplatin 8Capecitabine 8Bevacizumab 8Standard of Care 7Psychiatric Rehabilitation 7Fluorodeoxyglucose F18 7Early Intervention, Educational 7sargramostim 6palbociclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Sorafenib × Thoracic × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡